PA
MBX

Parallel Advisors’s MBX Biosciences MBX Stock Holding History

Parallel Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36K Buy
79
+18
+30% +$629 ﹤0.01% 3268
2026
Q1 		$1.82K Hold
61
– – ﹤0.01% 3401
2025
Q4 		$1.92K Hold
61
– – ﹤0.01% 3142
2025
Q3 		$1.07K Sell
61
-47
-44% -$628 ﹤0.01% 3205
2025
Q2 		$1.23K Buy
+108
New +$1.1K ﹤0.01% 3154

Other funds holding MBX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Parallel Advisors's MBX Position: Q2 2026 in Review

Parallel Advisors increased its MBX Biosciences (MBX) stake by 30% in Q2 2026, buying an estimated $629 and bringing the position to 79 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #3268.

Parallel Advisors first reported a position in MBX in Q2 2025 and has held it in 5 quarters since. 44 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Parallel Advisors held 79 shares of MBX Biosciences worth $4.36K as of Q2 2026.
  • Parallel Advisors bought 18 MBX Biosciences shares in Q2 2026, an estimated $629.
  • MBX Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3268 holding.
  • Parallel Advisors first reported a position in MBX Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 44 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.